EP0240098A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Oligo and polysaccharides for the treatment of diseases caused by retroviruses
Assignee: Ueno Seiyaku Oyo Kenkyujo KK
•
Filing: 1987-01-14
•
Granted: —
•
Expires: 2007-01-14
Abstract
Abstract The use of a natural or synthetic oligo- or polysaccharide having at least one S-oxoacid group attached to the saccharic carbon atom through a linking group of lower molecular weight or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treatment of diseases caused by retroviruses.
Inventors
- 👤 Ryuzo Ueno
- 👤 Ryuji Ueno
- 👤 Sachiko Kuno
- 👤 Akihiko Tabata
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 04:17
CPC Classifications
C; C07; C07H; C07H11/00; A; A61; A61K; A61K31/00; A61K31/70; A61K31/715
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
49 words
The use of a natural or synthetic oligo- or polysaccharide having at least one S-oxoacid group attached to the saccharic carbon atom through a linking group of lower molecular weight or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treatment of disease caused by retroviruses.
Claim 2
Dependent Claim
49 words
The use of a natural or synthetic oligo- or polysaccharide having at least one S-oxoacid group attached to the saccharic carbon atom through a linking group of lower molecular weight or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treatment of disease caused by retroviruses.
Claim 3
Dependent Claim
15 words
The use according to claim 1, wherein the said S-oxoacid group is sulfo group (-SO₃H).
Claim 4
Dependent Claim
17 words
The use according to claim 1, wherein the said linking group is oxy group(-O-) or imino group(-NH-).
Claim 5
Dependent Claim
22 words
The use according to claim 1, wherein the said treatment is prevention or therapy of PGL, ARC, AIDS, ATL, or Kawasaki disease.
Claim 6
Dependent Claim
13 words
The use according the claim 1, wherein the said retroviruses are human retroviruses.
Claim 7
Dependent Claim
21 words
The use according to claim 5, wherein the said human retroviruses are selected from HIVs such as HTLV-III, LAV, and ARV.
Claim 8
Dependent Claim
21 words
The use according to claim 5, wherein the said human retroviruses are selected form HTLV-I, HTLV-II and Kawasaki disease causative retroviruses.
Claim 9
Dependent Claim
13 words
The use according to claim 1, wherein the said retroviruses are animal retroviruses.
Claim 10
Dependent Claim
21 words
The use according to claim 1, wherein the said retroviruses are selected from avian myelobiastosis virus and Friend murine leukemia virus.
Claim 11
Dependent Claim
17 words
The use according to claim 1, wherein the said treatment is prevention from the infection with retroviruses.
Claim 12
Dependent Claim
12 words
The use according to claim 10, wherein the said retroviruses are HIVs.
Claim 13
Dependent Claim
21 words
The use according to claim 1, wherein the said oligo- or polysaccharide has ability of inhibiting reverse transcriptase of the retroviruses.
Claim 14
Dependent Claim
25 words
The use according to claim 1, wherein the said oligo- or polysaccharide is natural or synthetic polysaccharide sulfate ester or a pharmaceutically acceptable salt thereof.
Claim 15
Dependent Claim
65 words
The use according to claim 13, wherein the said natural or synthetic oligo- or polysaccharide is a natural polysaccharide having at least one hydrogen sulfate group(-O-SO₃H) obtained from a plant or a microorganism, or a synthetic polysaccharide having at least one hydrogen sulfate group(-O-SO₃H) formed by esterifying a polysaccharide obtained from a plant or a microorganism with sulfating agent, or a pharmaceutically acceptable salt thereof.
Claim 16
Dependent Claim
24 words
The use according to claim 14, wherein the said synthetic polysaccharide is selected from dextran sulfate alginic acid sulfate, lentinan sulfate and pururan sulfate.
Claim 17
Dependent Claim
36 words
The use according to claim 15, wherein the said dextran sulfate has a molecular wight between 500 and 2,000,000, ordinarily between 2,000 and 300,000, preferably between 2,000 and 10,000 and most suitably between 3,000 and 8,000.
Claim 18
Dependent Claim
31 words
The use according to claim 15, wherein the said dextran sulfate has a sulfur content between 5% and 22%, preferably between 10% and 20% and most suitably between 15% and 20%.
Claim 19
Dependent Claim
16 words
The use according to claim 14, wherein the said natural polysaccharide is selected from carrageenan, fucoidin.
Claim 20
Dependent Claim
57 words
The use according to claim 13, wherein the said natural or synthetic oligo- or polysaccharide is a natural polysaccharide having at least one sulfo group(-SO₃H) obtained from an animal, or a synthetic polysaccharide having at least one sulfo group(-SO₃H) formed by esterifying a polysaccharide obtained from an animal with sulfating agent, or a pharmaceutically acceptable salt thereof.
Claim 21
Dependent Claim
35 words
The use according to claim 19, wherein the said polysaccharide is a natural polysaccharide selected from mucopolysaccharide or a synthetic polysaccharide selected form mucopolysaccharide sulfate produced by esterifying a natural mucopolysaccharide with a sulfating agent.
Claim 22
Dependent Claim
18 words
The use according to claim 19, wherein the said polysaccharide is heparin or a pharmaceutically acceptable salt thereof.
Claim 23
Dependent Claim
61 words
The use according to claim 19, wherein the said polysaccharide is a natural polysaccharide selected from chondroitin sulfate, dermatan sulfate, heparitin sulfate, keratan sulfate, hyaluronic acid, teichronic acid, chitin and chitosan or synthetic polysaccharide selected from chondroitin polysulfate, dermatan polysulfate, heparitin polysulfate, keratan polysulfate, hyaluronic acid sulfate, teichronic acid sulphate, chitin sulfate and chitosan sulfate, or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.